Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Kao Su-Chin Chang, founder and chairman of Weidar Chemical and Pharmaceutical, describes the robust development and international expansion of this historical domestic pharmaceutical manufacturer and the company’s enduring commitment to…
Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of…
Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific…
Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have…
Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with…
In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to…
The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites…
The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and…
The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how…
The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will…
See our Cookie Privacy Policy Here